Smart medical device designer and manufacturer, EVEON,
and virtual trials & digital therapeutics platform, BEPATIENT, announce an exciting new strategic partnership.
Paris and Grenoble (France), 18th May, 2021: BEPATIENT, a pioneer in the development of virtual trials and digital therapeutics solutions, has signed a collaboration agreement with EVEON, designer and manufacturer of smart medical devices. The partnership will produce patient-centric digital solutions that serve both clinical research and digital therapeutics applications.
EVEON is a key player to make easily accessible molecules and new medicines, particularly with complex preparation or administration (biologics, lyophilisate to be reconstituted, dispersing powder, suspensions, dilutions, emulsions, combinations of therapies, highly viscous formulations, etc.) to the largest number of people. EVEON focuses on the design, development and industrialization of tailor-made connected medical devices for both drug preparation and drug delivery. In the context of this partnership, their unique technology Intuity ®, which guarantees safety and ease of use, will be used. Their innovative solutions can also be used to split doses of drugs in liquid form and perform multi-dose administrations using a single vial.
Meanwhile, BEPATIENT’s proprietary eHealth platform has been in agile development for more than ten years, and has produced innovations that enable direct-to-patient data collection for virtual clinical trials, as well as patient support, engagement and remote monitoring solutions for new digital therapies.
This new collaboration will integrate EVEON’s connected medical device into the BEPATIENT core platform, with a view to enabling tracking and remote management of medication adherence, and facilitating the handling, preparation and administration of specific drugs, in the context of both virtual clinical trials and digital therapeutics programs.
The new possibilities offered by EVEON complement the library of features already available on the BEPATIENT platform, including symptom-checking, scoring and algorithms, remote monitoring, and eLearning.
”Conscious of the challenges of the health sector and the current trend towards personalized medicine, BEPATIENT and EVEON cultivate an approach that focuses on the needs of patients and practitioners. With our shared know-how and expertise, we have the means to facilitate at-home patient treatment, improve patient compliance, and ensure reliability and ease of use of the therapy.Vincent TempelaereCEO of EVEON
”The collaboration with EVEON allows us to add value to our range by integrating a new type of connected devices into our portfolio. Beyond improving care pathways and patient engagement, thanks to IoTs and data intelligence, this partnership optimizes BEPATIENT's value proposition in the promising Digital Therapeutics market.Frederic Durand-SalmonCEO of BEPATIENT
BEPATIENT is a French company that has been developing since 2011 a comprehensive and modular core platform, enabling patients to be connected at home to Healthcare Professionals and to generate value-added Real-World Evidence (RWE) data. The BEPATIENT portfolio of solutions is structured around two activities: Clinical Research digitalization via direct-to-patient virtual trials technologies (ePRO, eCOA, eConsent, integration of connected devices, eCRF, etc.) and Digital Therapeutics: evidence-based Companion Apps integrating symptom checking, management of treatment adherence, remote monitoring, eLearning…
BEPATIENT’s activities are mainly concentrated in EMEA, with a wide range of therapeutic areas ( inflammatory diseases, immunology, oncology, cardiometabolic, chronic pain, neurosciences…) in several languages.
Press contact: Audrey Cohuet | email@example.com |
EVEON is an ISO 13485-certified company that designs and manufactures safe, connected automatic medical devices for the preparation and delivery of therapeutic treatments to improve patient quality of life. EVEON places the needs of patients and care professionals at the heart of its development by designing simple, intuitive devices to improve therapeutic performance, compliance, and the conditions of at-home care.
The company’s expertise has been recognized by Forbes magazines, which ranked EVEON as the 3rd most inventive company in France in the category of medical technology in 2019.
Press contact: Charlotte Reverand | firstname.lastname@example.org | @EVEON_SAS